Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
EMBO J ; 39(16): e103009, 2020 08 17.
Artigo em Inglês | MEDLINE | ID: mdl-32720716

RESUMO

Exosomes are secreted extracellular vesicles carrying diverse molecular cargos, which can modulate recipient cell behaviour. They are thought to derive from intraluminal vesicles formed in late endosomal multivesicular bodies (MVBs). An alternate exosome formation mechanism, which is conserved from fly to human, is described here, with exosomes carrying unique cargos, including the GTPase Rab11, generated in Rab11-positive recycling endosomal MVBs. Release of Rab11-positive exosomes from cancer cells is increased relative to late endosomal exosomes by reducing growth regulatory Akt/mechanistic Target of Rapamycin Complex 1 (mTORC1) signalling or depleting the key metabolic substrate glutamine, which diverts membrane flux through recycling endosomes. Vesicles produced under these conditions promote tumour cell proliferation and turnover and modulate blood vessel networks in xenograft mouse models in vivo. Their growth-promoting activity, which is also observed in vitro, is Rab11a-dependent, involves ERK-MAPK-signalling and is inhibited by antibodies against amphiregulin, an EGFR ligand concentrated on these vesicles. Therefore, glutamine depletion or mTORC1 inhibition stimulates release from Rab11a compartments of exosomes with pro-tumorigenic functions, which we propose promote stress-induced tumour adaptation.


Assuntos
Proliferação de Células , Exossomos , Glutamina/deficiência , Sistema de Sinalização das MAP Quinases , Neoplasias , Animais , Proteínas de Drosophila/genética , Proteínas de Drosophila/metabolismo , Drosophila melanogaster , Exossomos/genética , Exossomos/metabolismo , Exossomos/patologia , Alvo Mecanístico do Complexo 1 de Rapamicina/genética , Alvo Mecanístico do Complexo 1 de Rapamicina/metabolismo , Neoplasias/genética , Neoplasias/metabolismo , Neoplasias/patologia , Proteínas rab de Ligação ao GTP/genética , Proteínas rab de Ligação ao GTP/metabolismo
2.
J Extracell Vesicles ; 13(6): e12465, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38887984

RESUMO

Exosomes are secreted vesicles made intracellularly in the endosomal system. We have previously shown that exosomes are not only made in late endosomes, but also in recycling endosomes marked by the monomeric G-protein Rab11a. These vesicles, termed Rab11a-exosomes, are preferentially secreted under nutrient stress from several cancer cell types, including HCT116 colorectal cancer (CRC) cells. HCT116 Rab11a-exosomes have particularly potent signalling activities, some mediated by the epidermal growth factor receptor (EGFR) ligand, amphiregulin (AREG). Mutant activating forms of KRAS, a downstream target of EGFR, are often found in advanced CRC. When absent, monoclonal antibodies, such as cetuximab, which target the EGFR and block the effects of EGFR ligands, such as AREG, can be administered. Patients, however, inevitably develop resistance to cetuximab, either by acquiring KRAS mutations or via non-genetic microenvironmental changes. Here we show that nutrient stress in several CRC cell lines causes the release of AREG-carrying Rab11a-exosomes. We demonstrate that while soluble AREG has no effect, much lower levels of AREG bound to Rab11a-exosomes from cetuximab-resistant KRAS-mutant HCT116 cells, can suppress the effects of cetuximab on KRAS-wild type Caco-2 CRC cells. Using neutralising anti-AREG antibodies and an intracellular EGFR kinase inhibitor, we show that this effect is mediated via AREG activation of EGFR, and not transfer of activated KRAS. Therefore, presentation of AREG on Rab11a-exosomes affects its ability to compete with cetuximab. We propose that this Rab11a-exosome-mediated mechanism contributes to the establishment of resistance in cetuximab-sensitive cells and may explain why in cetuximab-resistant tumours only some cells carry mutant KRAS.


Assuntos
Anfirregulina , Cetuximab , Neoplasias Colorretais , Resistencia a Medicamentos Antineoplásicos , Exossomos , Proteínas rab de Ligação ao GTP , Humanos , Anfirregulina/metabolismo , Cetuximab/farmacologia , Exossomos/metabolismo , Neoplasias Colorretais/metabolismo , Neoplasias Colorretais/genética , Neoplasias Colorretais/tratamento farmacológico , Proteínas rab de Ligação ao GTP/metabolismo , Receptores ErbB/metabolismo , Células HCT116 , Antineoplásicos Imunológicos/farmacologia , Linhagem Celular Tumoral , Estresse Fisiológico , Proteínas Proto-Oncogênicas p21(ras)/metabolismo , Proteínas Proto-Oncogênicas p21(ras)/genética , Transdução de Sinais/efeitos dos fármacos
3.
Curr Opin Genet Dev ; 27: 20-5, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24791689

RESUMO

The ability of a cell to transform an extracellular stimulus into a downstream event that directs specific physiological outcomes, requires the orchestrated, spatial and temporal response of many signalling proteins. The notion of compartmentalised signalling pathways was popularised in the 1980s by Brunton and colleagues, with their discovery that spatially segregated cAMP directs a variety of signalling responses in cardiomyocytes. It is now understood that compartmentalisation is a common mechanism used by all cells to ensure the interaction of signalling 'second messenger' molecules with localised 'pools' of appropriate effector proteins. In this way, the cell can elicit differential cellular responses by using a single, freely diffusible, molecular species. Recently, the compartmentalisation schemes employed by signalling systems involving cyclic nucleotides, calcium and nitric oxide have been elucidated and as a result, the varied range of functional consequences underpinned by such strategies can be better appreciated.


Assuntos
Sistemas do Segundo Mensageiro , Animais , Cálcio/metabolismo , AMP Cíclico/metabolismo , GMP Cíclico/metabolismo , Humanos , Óxido Nítrico/metabolismo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa